

# Press Release

Malmö, SWEDEN – November 20, 2007

## Chairman of the Board acquires shares

Through a holding company, Hansa Medical's Chairman of the Board, Bo Håkansson, has increased his shareholding in Hansa Medical AB by 52,500 shares. Following the acquisition, Bo Håkansson's holding company, Farstorps Gård Förvaltnings AB, now holds 1,465,489 shares in Hansa Medical, corresponding to a participating interest of 37.3 percent.

The Hansa Medical share has been traded on First North under the ticker symbol HMED since October 17, 2007, and the company's certified adviser is Kaupthing Bank.

For more information, please contact:

**Emanuel Björne, CEO**

Mobile: +46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

**Bo Håkansson, Chairman of the Board**

Mobile: +46 705 98 57 22

E-mail: [bo.hakansson@farstorp.com](mailto:bo.hakansson@farstorp.com)

### ABOUT HANSA MEDICAL

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company's long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical's lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including diagnostics and drugs for sepsis.

Hansa Medical AB  
CRC Entrance 72  
UMAS  
SE-205 02 Malmö, Sweden  
TELEPHONE +46 40 849 93  
FAX +46 40 817 35

[info@hansamedical.com](mailto:info@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

VISITING ADDRESS:  
Clinical Research Centre at  
Malmö University Hospital  
Entrance 72  
Malmö, Sweden